Substituted biaryl compounds as factor XIa inhibitors

A compound of Formula (I):

• or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof, wherein:
• A is cyclohexyl substituted with 0-1 R1 and 0-3 R2;
• provided that A is other than cyclohexyl substituted with CN;
• ring B is phenyl optionally further substituted with 0-3 R4;
• Z is —CHR11—;
• L is —C(O)NR10—;
• R1 is, independently at each occurrence, H, —NH2, —NH(C1-3 alkyl), —(CH2)rNR7R8,—CH(C1-4 alkyl)NH2, —CH(C1-4 alkyl)2NH2, —N(C1-3 alkyl)2, —C(═NH)NH2, —C(O)NH2, —CH2NH2, —CH2NH(C1-3 alkyl), —CH2N(C1-3 alkyl)2,—CH2CH2NH2, —CH2CH2NH(C1-3 alkyl), —CH2CH2N(C1-3 alkyl)2, OCF3, CF3, ORa, SRa, CN or C1-6 alkyl;
• R2 is, independently at each occurrence, H, ═O, CF3, OCF3, CHF2, CN, NO2, ORa, SRa, —NR7R8, or C1-6 alkyl;
• R3 is a heterocycle selected from:
• benzisoxazole, indazole, quinoline, tetrahydroquinoline, phthalazine, and quinazoline, wherein said heterocycle is substituted with 0-3 R3a;
• R3a is, independently at each occurrence, ═O, F, Cl, Br, I, OCF3, CF3, —(CH2)rCN, NO2, —(CH2)rOR3b, —(CH2)r—SR3b, —(CH2)rNR7R8, —C(O)C1-4 alkyl, —SO2NHR3b, —(CH2)rNR8CO2R3b, —(CH2)rS(O)pNR8R9, —S(O)R3c, —S(O)2R3c, —(CH2)rCO2R3b, —(CH2)rC(O)NR8R9, C1-4 haloalkyl, C1-4 haloalkyloxy-, or C1-6 alkyl;
• R3b is, independently at each occurrence, H, or C1-6 alkyl;
• R3C is, independently at each occurrence, C1-6 alkyl
• R4 is, independently at each occurrence, H, F, Cl, Br, I, OCF3 , CF3, CN, NO2, ORa, SRa, —C(O)Ra, —C(O)ORa, —OC(O)Ra, —NR7R8, —C(O)NR8R9, —NR8C(O)Rb, —NR8C(O)ORb, —S(O)Rc, —S(O)2Rc, or C1-6 alkyl
• R7 is, independently at each occurrence, H, C1-4 alkyl, —C(O)(C1-4 alkyl), or —(CH2)n-phenyl;
• R8 is, independently at each occurrence, H, C1-6 alkyl, or —(CH2)n-phenyl;
• R9 is, independently at each occurrence, H, C1-6 alkyl, or —(CH2)n-phenyl;
• R10 is, independently at each occurrence, H, or C1-6 alkyl substituted with 0-2 F;
• R11 is —(CH2)s-phenyl substituted with 0-2 R11b;
• R11b is, independently at each occurrence, H, ORa, SRa, F, Cl, Br, CN, NO2, CF3, OCF3, OCHF2, —NR7R8, —C(O)Ra, —C(O)ORa, —C(O)NR7R8, —CH2ORa, —CH2NR7R8, —NR8C(O)Rb, —S(O)pNR8R9, —NR8S(O)pRc,—S(O)pRc, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C1-4 haloalkyl, or C1-4 haloalkyloxy;
• Ra is, independently at each occurrence, H, CF3, C1-6 alkyl, —(CH2)r—C3-7 cycloalkyl, or —(CH2)r—C6-10 aryl;
• Rb is, independently at each occurrence, CF3, OH, C1-4 alkoxy, or C1-6 alkyl;
• Rc is, independently at each occurrence, CF3, or C1-6 alkyl;
• r, at each occurrence, is selected from 0, 1, 2, 3, and 4;
• n, at each occurrence, is selected from 0, 1, 2, 3, and 4;
• p, at each occurrence, is selected from 0, 1, and 2;
• and
• s, at each occurrence, is selected from 1, 2, 3, and 4.